IL2 and cancer: TILT-123 (igrelimogene litadenorepvec) is an engineered OVs that selectively replicates in cancer cells and expresses dual transgenes IL-2 and TNF-α, designed to enhance tumor immune infiltration and cytotoxic T-cell responses [187].